Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2008

View Archived Issues

Inhibition of ErbB3 receptor by EZN-3920 shows antitumor activity in preclinical studies

MTD established in a phase I advanced cancer study of oral c-Met inhibitor ARQ-197

Novel class of antibacterial pyrrolamides targeting DNA gyrase identified

ARRY-162 safe, affects biomarkers in phase I studies

Increased exposure seen with deuterated linezolid compared with linezolid in vivo

Allergan reviews Q3 accomplishments

ArQule and Daiichi Sankyo enter strategic R&D cancer program

Azur and Elan sign agreement to develop once-daily clozapine

EntreMed meets primary efficacy endpoint in phase I/II NSCLC trial

ProtoKinetix receives independent confirmation of AAGP antiinflammatory action

FDA clears Celgene's placenta-derived stem cells for first clinical study

FDA and DOR agree on design of phase III study of orBec in GI GVHD

Dosing is initiated in INFORM-1 clinical trial of R-7227 and R-7128 for HCV

Aradigm announces results from clinical trial of inhaled treprostinil with AERx inhaler

Amgen provides pipeline update at recent investors meeting

GSK and XenoPort plan to withdraw and resubmit Solzira NDA for RLS

Xoma restructures drug development collaboration with Novartis

Insmed gains royalty-free worldwide rights for Iplex for ALS

TorreyPines sells AD genetics program to Eisai, enabling advancement of clinical-stage assets

Optimer presents data from North American phase III OPT-80 study

Recent patents disclose novel therapeutic agents for asthma and other indications

New treatment options for urological disorders reported in recent patents

Novel agents for psychiatric disorders described in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...